RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. Their team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. They invest in companies with promising technologies and products. Their approach is to achieve a superior understanding of data, experimental/trial design, regulatory process, and commercial potential. When appropriate, they can offer their portfolio companies leads on in-licensing opportunities and strategic partnerships, as well as insight into the demands of the public markets.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 7, 2022
Apogee Therapeutics
|
Series B | $149M | Biotechnology | — |
Dec 7, 2022
Vor Biopharma
|
Post-IPO Equity | $115.80M | Biotechnology | Yes |
Nov 15, 2022
Jnana Therapeutics
|
Series C | $107M | Biotechnology | — |
Nov 14, 2022
MBX Biosciences
|
Series B | $115M | Biotechnology | — |
Sep 12, 2022
Nimbus Therapeutics
|
Series Unknown | $125M | Biotechnology | — |